Effect of the Olive Leaf Tea Ingestion in Post-prandial Glycemic Response (OLIFTEA)

NCT ID: NCT05397509

Last Updated: 2022-05-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-04-29

Study Completion Date

2022-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This study tests the effect of Olive Tea Ingestion in ameliorating glycemic response after a high-glycemic meal

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This study is a double-blinded, randomized, placebo-controlled clinical trial with cross-over design.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Blood Glucose

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Each participant will test one beverage on the first visit and the other one on the second visit. A wash-out period of two weeks will be done.

Allocation of the first beverage to each participant is made by randomization.
Primary Study Purpose

PREVENTION

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors
olive leaf tea and placebo tea were offered in a opaque mug

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Olive Leaf Tea

Olive Leaf Tea

Group Type EXPERIMENTAL

Olive leaf tea

Intervention Type OTHER

250 mL of Olive leaf tea and a high-glycemic breakfast

Placebo tea

Placebo tea

Group Type PLACEBO_COMPARATOR

Placebo tea

Intervention Type OTHER

250 mL of placebo tea and a high-glycemic breakfast

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Olive leaf tea

250 mL of Olive leaf tea and a high-glycemic breakfast

Intervention Type OTHER

Placebo tea

250 mL of placebo tea and a high-glycemic breakfast

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

\-

Exclusion Criteria

* currently taking drugs interfering with glucose regulation
Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Instituto Politécnico de Bragança

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Manuela Meireles

Researcher

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manuela Meireles, PhD

Role: PRINCIPAL_INVESTIGATOR

Instituto Politécnico de Bragança

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

escola Superior de Saúde

Bragança, , Portugal

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Portugal

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Manuela Meireles, PhD

Role: CONTACT

Phone: 273330984

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Manuela Meireles, PhD

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

361221

Identifier Type: -

Identifier Source: org_study_id